The new journal club for Tuesday is a study of atrasentan for diabetic kidney disease. When I wrote introduction post I went to wikipedia and learned that atrasentan had been in trials as an antineoplastic agent. I went to the Twitter and asked if anyone was using it.
@MarkGaze is atrasartan still being investigated as a cancer treatment?
— Joel Topf (@kidney_boy) May 9, 2014
@kidney_boy Not to my personal knowledge. Also US National Cancer Institute clinical trials database doesn't come up with anything either.
— MD FRCP FRCR (@MarkGaze) May 9, 2014
He then gave me the keys to the kingdom by showing me where to search NCI site for trials. Bingo.
“@MarkGaze: @kidney_boy http://t.co/HCSwEbjGQB then enter the name of the drug as a keyword and press search.”
— Joel Topf (@kidney_boy) May 9, 2014
I was Quickly able to find the failed phase 3 trial and updated wikipedia.
@kidney_boy 994 patients required to demonstrate futility! We never get patient numbers like that in our paediatric trials.
— MD FRCP FRCR (@MarkGaze) May 9, 2014